TABLE 4.
Percentage of CpG promoter methylation after chrysin treatment as compared to untreated control. The values are taken as mean of three experiments ±SD (p ≤ 0.05).
| Target name | Gene name | Untreated control | Chrysin 10 µM | Chrysin 15 µM |
|---|---|---|---|---|
| APC | Adenomatous polyposis 1 | 24.20 | 7.88 | 2.72 |
| BRCA1 | Breast cancer gene 1 | 79.49 | 18.12 | 2.11 |
| CDH1 | E-cadherin | 76.91 | 55.01 | 43.25 |
| CDH13 | H-cadherin | 68.56 | 38.89 | 2.60 |
| CDKN2A | Cyclin-dependent inhibitor 2A | 27.74 | 14.43 | 4.19 |
| DAPK1 | Death-associated protein kinase 1 | 36.49 | 17.06 | 11.46 |
| FHIT | Fragile histidine triad protein | 19.35 | 5.04 | 2.94 |
| GSTP1 | Glutathione S-transferase Pi 1 | 30.80 | 6.88 | 3.11 |
| MGMT | O-6-Methylguanine-dna methyltransferase | 34.38 | 13.99 | 4.29 |
| MLH1 | Mutl homolog 1 | 28.49 | 21.88 | 14.50 |
| PTEN | Phosphatase and tensin homolog | 25.43 | 14.11 | 11.30 |
| RARB | Retinoic acid receptor beta | 45.47 | 21.88 | 11.22 |
| RASSF1 | Ras association domain family member 1 | 30.71 | 19.24 | 15.27 |
| SOC51 | Suppressor of cytokine signaling 1 | 85.82 | 73.50 | 56.97 |
| TIMP3 | Metalloproteinase inhibitor 3 | 24.44 | 13.49 | 3.32 |
| VHL | Von Hippel–Lindau tumor suppressor | 31.10 | 14.59 | 11.78 |
| WIF1 | Wnt inhibitory factor 1 | 98.14 | 82.56 | 60.68 |